Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminated
NCT03368664Phase 3Updated Aug 4, 2026
Sponsor: Genzyme, a Sanofi Company
Multiple Sclerosis
France, Italy, Poland, Russia, Turkey (Türkiye) +1 more
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and AboveCompleted
NCT06361875Phase 1, Phase 2Updated Aug 4, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
United States, Honduras, Puerto Rico
A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminated
NCT06705140Phase 3Updated Aug 3, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
RSV Immunisation · Healthy Volunteers
Honduras
ETIC (Therapeutic Education in Heart Failure)Active Not Recruiting
NCT01065142NAUpdated Aug 3, 2026
Sponsor: University Hospital, Clermont-Ferrand
Heart Failure · Quality of Life
France
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous UrticariaTerminated
NCT07316114N/AUpdated Jul 31, 2026
Sponsor: Sanofi
Chronic Spontaneous Urticaria
United States
Quantitative MRI for MyelofibrosisRecruiting
NCT01973881N/AUpdated Jul 31, 2026
Sponsor: University of Michigan Rogel Cancer Center
Myelofibrosis
United States
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical RoutineActive Not Recruiting
NCT06087627N/AUpdated Jul 31, 2026
Sponsor: Sanofi
Prurigo Nodularis
Germany
RSV Immunisation Status in Queensland (Australia)Recruiting
NCT07615192N/AUpdated Jul 31, 2026
Sponsor: Sanofi
RSV Immunization
Australia
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling By Invitation
NCT05669989Phase 2Updated Jul 31, 2026
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Australia, Brazil, Chile, China +12 more
Dupilumab in CRSsNPCompleted
NCT04678856Phase 2Updated Jul 30, 2026
Sponsor: Sanofi
Chronic Rhinosinusitis Without Nasal Polyps · Sinusitis · Chronic Sinusitis · Sinus Disorder
United States, Argentina, Belgium, Canada, Chile +8 more
Tdap Vaccination During Pregnancy or Postpartum and Lactation-Related OutcomesCompleted
NCT07735767N/AUpdated Jul 30, 2026
Sponsor: HealthPartners Institute
Pertussis Vaccines
Societal Burden Associated With Type 1 Diabetes in CanadaTerminated
NCT06786130N/AUpdated Jul 30, 2026
Sponsor: PeriPharm
Type 1 Diabetes Mellitus · Quality of Life (QOL) · Work Productivity · Caregiver Subjective Burden
Canada
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction CancerCompleted
NCT00183898Phase 2Updated Jul 30, 2026
Sponsor: University of Southern California
Gastric Cancer · Esophageal Cancer
United States
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseRecruiting
NCT06975865Phase 3Updated Jul 29, 2026
Sponsor: Sanofi
Sickle Cell Disease
United States, Belgium, Brazil, France, Germany +8 more
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis BronchiectasisSuspended
NCT07547436Phase 2Updated Jul 29, 2026
Sponsor: Sanofi
Non-cystic Fibrosis Bronchiectasis
United States
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic EventsActive Not Recruiting
NCT07734753N/AUpdated Jul 29, 2026
Sponsor: Sanofi
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Netherlands
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderRecruiting
NCT07734649Phase 1, Phase 2Updated Jul 29, 2026
Sponsor: Sanofi
Respiratory Syncytial Virus Immunization · Human Metapneumovirus Immunization · Healthy Volunteers
United States
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)Completed
NCT04458831N/AUpdated Jul 29, 2026
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Argentina, Austria, Belgium, China +16 more
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Recruiting
NCT06290141Phase 3Updated Jul 29, 2026
Sponsor: Sanofi
Chronic Inflammatory Demyelinating Polyneuropathy
United States, Argentina, Belgium, Brazil, Canada +18 more
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of KoreaRecruiting
NCT07621653N/AUpdated Jul 29, 2026
Sponsor: Sanofi
Meningococcal Immunization · Healthy Volunteers
South Korea
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramEnrolling By Invitation
NCT05368038N/AUpdated Jul 28, 2026
Sponsor: Albert Einstein College of Medicine
Acid Sphingomyelinase Deficiency · Ceroid Lipofuscinosis, Neuronal, 2 · Cerebrotendinous Xanthomatosis · Fabry Disease
United States
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseRecruiting
NCT07190196Phase 3Updated Jul 28, 2026
Sponsor: Sanofi
Immunoglobulin G4 Related Disease
United States, Argentina, Belgium, Canada, Chile +14 more
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic DermatitisRecruiting
NCT07467564N/AUpdated Jul 28, 2026
Sponsor: Sanofi
Atopic Dermatitis
Qatar, Saudi Arabia, United Arab Emirates
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia AActive Not Recruiting
NCT04644575Phase 3Updated Jul 28, 2026
Sponsor: Bioverativ, a Sanofi company
Hemophilia A
United States, Argentina, Australia, Belgium, Brazil +18 more
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV VaccineCompleted
NCT03284710Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Mozambique, South Africa, Zimbabwe

Previous page Next page